Literature DB >> 19495749

Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data.

Sargo Aalto1, Noora M Scheinin, Nina M Kemppainen, Kjell Någren, Marita Kailajärvi, Mika Leinonen, Mika Scheinin, Juha O Rinne.   

Abstract

PURPOSE: Positron emission tomography (PET) with 11C-labelled Pittsburgh compound B ([11C]PIB) enables the quantitation of beta-amyloid accumulation in the brain of patients with Alzheimer's disease (AD). Voxel-based image analysis techniques conducted in a standard brain space provide an objective, rapid and fully automated method to analyze [11C]PIB PET data. The purpose of this study was to evaluate both region- and voxel-level reproducibility of automated and simplified [11C]PIB quantitation when using only 30 min of imaging data.
METHODS: Six AD patients and four healthy controls were scanned twice with an average interval of 6 weeks. To evaluate the feasibility of short scanning (convenient for AD patients), [11C]PIB uptake was quantitated using 30 min of imaging data (60 to 90 min after tracer injection) for region-to-cerebellum ratio calculations. To evaluate the reproducibility, a test-retest design was used to derive absolute variability (VAR) estimates and intraclass correlation coefficients at both region-of-interest (ROI) and voxel level.
RESULTS: The reproducibility both at the region level (VAR 0.9-5.5%) and at the voxel level (VAR 4.2-6.4%) was good to excellent. Based on the variability estimates obtained, power calculations indicated that 90% power to obtain statistically significant difference can be achieved using a sample size of five subjects per group when a 15% change from baseline (increase or decrease) in [11C]PIB accumulation in the frontal cortex is anticipated in one group compared to no change in another group.
CONCLUSION: Our results showed that an automated analysis method based on an efficient scanning protocol provides reproducible results for [11C]PIB uptake and appears suitable for PET studies aiming at the quantitation of amyloid accumulation in the brain of AD patients for the evaluation of progression and treatment effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19495749     DOI: 10.1007/s00259-009-1174-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  18 in total

1.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

Authors:  Brian J Lopresti; William E Klunk; Chester A Mathis; Jessica A Hoge; Scott K Ziolko; Xueling Lu; Carolyn C Meltzer; Kurt Schimmel; Nicholas D Tsopelas; Steven T DeKosky; Julie C Price
Journal:  J Nucl Med       Date:  2005-12       Impact factor: 10.057

2.  Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease.

Authors:  Anna Brück; Sargo Aalto; Elina Nurmi; Jörgen Bergman; Juha O Rinne
Journal:  Neurobiol Aging       Date:  2005-06       Impact factor: 4.673

3.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Authors:  Henry Engler; Anton Forsberg; Ove Almkvist; Gunnar Blomquist; Emma Larsson; Irina Savitcheva; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Brain       Date:  2006-07-19       Impact factor: 13.501

4.  Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease.

Authors:  Scott K Ziolko; Lisa A Weissfeld; William E Klunk; Chester A Mathis; Jessica A Hoge; Brian J Lopresti; Steven T DeKosky; Julie C Price
Journal:  Neuroimage       Date:  2006-08-14       Impact factor: 6.556

5.  Assessment of spatial normalization of PET ligand images using ligand-specific templates.

Authors:  J H Meyer; R N Gunn; R Myers; P M Grasby
Journal:  Neuroimage       Date:  1999-05       Impact factor: 6.556

6.  PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.

Authors:  N M Kemppainen; S Aalto; I A Wilson; K Någren; S Helin; A Brück; V Oikonen; M Kailajärvi; M Scheinin; M Viitanen; R Parkkola; J O Rinne
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

7.  Measurement of GABAA receptor binding in vivo with [11C]flumazenil: a test-retest study in healthy subjects.

Authors:  Elina Salmi; Sargo Aalto; Jussi Hirvonen; Jaakko W Långsjö; Anu T Maksimow; Vesa Oikonen; Liisa Metsähonkala; Jussi Virkkala; Kjell Någren; Harry Scheinin
Journal:  Neuroimage       Date:  2008-03-04       Impact factor: 6.556

8.  Voxel-based analysis of 11C-PIB scans for diagnosing Alzheimer's disease.

Authors:  Arthur Mikhno; Davangere Devanand; Gregory Pelton; Katrina Cuasay; Roger Gunn; Neil Upton; Robert Y Lai; Vincenzo Libri; J John Mann; Ramin V Parsey
Journal:  J Nucl Med       Date:  2008-07-16       Impact factor: 10.057

9.  Imaging beta-amyloid burden in aging and dementia.

Authors:  C C Rowe; S Ng; U Ackermann; S J Gong; K Pike; G Savage; T F Cowie; K L Dickinson; P Maruff; D Darby; C Smith; M Woodward; J Merory; H Tochon-Danguy; G O'Keefe; W E Klunk; C A Mathis; J C Price; C L Masters; V L Villemagne
Journal:  Neurology       Date:  2007-05-15       Impact factor: 9.910

10.  Unidirectional Influx and Net Accumulation of PIB.

Authors:  Gunnar Blomquist; Henry Engler; Agneta Nordberg; Anna Ringheim; Anders Wall; Anton Forsberg; Sergio Estrada; Pernilla Frändberg; Gunnar Antoni; Bengt Långström
Journal:  Open Neuroimag J       Date:  2008-11-13
View more
  15 in total

1.  Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Methodology for Research and Clinical Brain PET Applications.

Authors:  Fabio Raman; Sameera Grandhi; Charles F Murchison; Richard E Kennedy; Susan Landau; Erik D Roberson; Jonathan McConathy
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

2.  Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease.

Authors:  Timo Grimmer; Susanne Tholen; Behrooz H Yousefi; Panagiotis Alexopoulos; Annette Förschler; Hans Förstl; Gjermund Henriksen; William E Klunk; Chester A Mathis; Robert Perneczky; Christian Sorg; Alexander Kurz; Alexander Drzezga
Journal:  Biol Psychiatry       Date:  2010-07-02       Impact factor: 13.382

3.  Visual assessment of [(11)C]PIB PET in patients with cognitive impairment.

Authors:  Timo Suotunen; Jussi Hirvonen; Pirjo Immonen-Räihä; Sargo Aalto; Irina Lisinen; Eveliina Arponen; Mika Teräs; Kari Koski; Raimo Sulkava; Marko Seppänen; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-09       Impact factor: 9.236

4.  Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI.

Authors:  N M Kemppainen; N M Scheinin; J Koivunen; J Johansson; J T Toivonen; K Någren; J Rokka; M Karrasch; R Parkkola; J O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

Review 5.  Spatial normalization and quantification approaches of PET imaging for neurological disorders.

Authors:  Teng Zhang; Shuang Wu; Xiaohui Zhang; Yiwu Dai; Anxin Wang; Hong Zhang; Mei Tian
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-28       Impact factor: 10.057

6.  Intravenous ethanol increases dopamine release in the ventral striatum in humans: PET study using bolus-plus-infusion administration of [(11)C]raclopride.

Authors:  Sargo Aalto; Kimmo Ingman; Kati Alakurtti; Valtteri Kaasinen; Jussi Virkkala; Kjell Någren; Juha O Rinne; Harry Scheinin
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

7.  Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer's disease.

Authors:  Tobias Tuszynski; Michael Rullmann; Julia Luthardt; Daniel Butzke; Solveig Tiepolt; Hermann-Josef Gertz; Swen Hesse; Anita Seese; Donald Lobsien; Osama Sabri; Henryk Barthel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-07       Impact factor: 9.236

8.  Resting-state glucose metabolism level is associated with the regional pattern of amyloid pathology in Alzheimer's disease.

Authors:  Jonghan Shin; Wai Tsui; Yi Li; Sang-Yoon Lee; Seog Ju Kim; Seong-Jin Cho; Young-Bo Kim; Mony J de Leon
Journal:  Int J Alzheimers Dis       Date:  2011-03-17

9.  A European multicentre PET study of fibrillar amyloid in Alzheimer's disease.

Authors:  Agneta Nordberg; Stephen F Carter; Juha Rinne; Alexander Drzezga; David J Brooks; Rik Vandenberghe; Daniela Perani; Anton Forsberg; Bengt Långström; Noora Scheinin; Mira Karrasch; Kjell Någren; Timo Grimmer; Isabelle Miederer; Paul Edison; Aren Okello; Koen Van Laere; Natalie Nelissen; Mathieu Vandenbulcke; Valentina Garibotto; Ove Almkvist; Elke Kalbe; Rainer Hinz; Karl Herholz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-08       Impact factor: 9.236

10.  MR-less surface-based amyloid assessment based on 11C PiB PET.

Authors:  Luping Zhou; Olivier Salvado; Vincent Dore; Pierrick Bourgeat; Parnesh Raniga; S Lance Macaulay; David Ames; Colin L Masters; Kathryn A Ellis; Victor L Villemagne; Christopher C Rowe; Jurgen Fripp
Journal:  PLoS One       Date:  2014-01-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.